Literature DB >> 14519094

A novel mutation in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia in a family with two uncommon parathyroid hormone polymorphisms.

D Alvarez-Hernández1, I Santamaría, M Rodríguez-García, P Iglesias, R Delgado-Lillo, J B Cannata-Andía.   

Abstract

A novel missense activating mutation in the extracellular calcium-sensing receptor (CaSR) is reported in this work. It was identified in three related subjects with the phenotypic features of autosomal dominant hypocalcemia (ADH). The proband, a 27-year-old woman, diagnosed as having hypoparathyroidism at 7 years of age and a history of seizures, showed the highest penetrance of the mutation. The remaining two affected members presented asymptomatic chronic hypocalcemia despite severe hypoparathyroidism associated with high levels of serum phosphate and calcium urinary excretion. The missense mutation (Glu(604)Lys) affected an amino acid residue in the C terminus of the cysteine-rich domain of the extracellular amino-terminal domain, which seems to be required for the coupling of ligand binding to the activation of intracellular signaling pathways. This genetic change cosegregated with hypocalcemia in all the individuals where the mutation was found. As parathyroid hormone (PTH) secretion is the regulatory target of the CaSR, polymorphism analysis of the PTH gene was carried out. PTH polymorphisms were analyzed in the kindred studied. Affected members for the Glu(604)Lys CaSR mutation which also carried the uncommon PTH alleles showed higher penetrance of the mutation, with more severe autosomal dominant hypocalcemia. These results suggested that the PTH gene could act as a modifier locus of ADH, affecting the penetrance of the activating CaSR mutation described.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519094     DOI: 10.1677/jme.0.0310255

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  4 in total

Review 1.  Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Authors:  Diego Brancaccio; Jürgen Bommer; Daniel Coyne
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene.

Authors:  Barbora Obermannova; Karolina Banghova; Zdenek Sumník; Hana M Dvorakova; Jan Betka; Filip Fencl; Stanislava Kolouskova; Ondrej Cinek; Jan Lebl
Journal:  Eur J Pediatr       Date:  2008-08-27       Impact factor: 3.183

3.  Sequencing the CaSR locus in Pakistani stone formers reveals a novel loss-of-function variant atypically associated with nephrolithiasis.

Authors:  Muhammad Yasir Zahoor; Amar J Majmundar; Ihsan Ullah; Isabel Ottlewski; Wasim Shehzad; Amjad Riaz; Sadaqat Ijaz; Asad Tufail; Hafiza Ammara; Shrikant Mane; Shirlee Shril; Friedhelm Hildebrandt
Journal:  BMC Med Genomics       Date:  2021-11-12       Impact factor: 3.622

4.  Identification of p.Arg205Cys in CASR in an autosomal dominant hypocalcaemia type 1 pedigree: A case report.

Authors:  Yubing Ji; Chunyang Kang; Jiajun Chen; Lei Zhang
Journal:  Medicine (Baltimore)       Date:  2021-06-25       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.